Jules Gadiot

1.8k total citations
21 papers, 1.1k citations indexed

About

Jules Gadiot is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jules Gadiot has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Jules Gadiot's work include CAR-T cell therapy research (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Melanoma and MAPK Pathways (7 papers). Jules Gadiot is often cited by papers focused on CAR-T cell therapy research (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Melanoma and MAPK Pathways (7 papers). Jules Gadiot collaborates with scholars based in Netherlands, United States and United Kingdom. Jules Gadiot's co-authors include Anna I. Hooijkaas, Christian U. Blank, Andrew Kaiser, Hester van Boven, Harm van Tinteren, Robert L. Bowman, Colin Watts, Dieta Brandsma, Daniela F. Quail and Marnix H. P. de Groot and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Jules Gadiot

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jules Gadiot Netherlands	14	641	483	461	139	131	21	1.1k
Tyler Alban United States	15	377 0.6×	307 0.6×	397 0.9×	163 1.2×	95 0.7×	33	938
Maria Georganaki Sweden	11	393 0.6×	258 0.5×	315 0.7×	115 0.8×	117 0.9×	12	711
Frederick S. Varn United States	16	513 0.8×	358 0.7×	410 0.9×	286 2.1×	232 1.8×	28	1.0k
Tina Verschuere Belgium	17	404 0.6×	307 0.6×	641 1.4×	82 0.6×	128 1.0×	21	1.0k
Arnaud Jabouille France	8	489 0.8×	454 0.9×	378 0.8×	183 1.3×	143 1.1×	8	1.1k
Frank J. Lowery United States	14	580 0.9×	565 1.2×	408 0.9×	140 1.0×	197 1.5×	26	1.1k
Megan K. Ruhland United States	8	571 0.9×	463 1.0×	764 1.7×	145 1.0×	102 0.8×	10	1.3k
Verlene Henry United States	14	473 0.7×	544 1.1×	468 1.0×	290 2.1×	124 0.9×	17	1.2k
Mélanie Tichet France	16	441 0.7×	674 1.4×	303 0.7×	196 1.4×	88 0.7×	20	1.1k

Countries citing papers authored by Jules Gadiot

Since Specialization

Citations

This map shows the geographic impact of Jules Gadiot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jules Gadiot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jules Gadiot more than expected).

Fields of papers citing papers by Jules Gadiot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jules Gadiot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jules Gadiot. The network helps show where Jules Gadiot may publish in the future.

Co-authorship network of co-authors of Jules Gadiot

This figure shows the co-authorship network connecting the top 25 collaborators of Jules Gadiot. A scholar is included among the top collaborators of Jules Gadiot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jules Gadiot. Jules Gadiot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ma, Jennifer, Xiangjun Kong, Paula Kroon, et al.. (2024). Non-clinical evaluation of NT-112, an autologous T cell product engineered to express an HLA-C*08:02-restricted TCR targeting KRAS G12D and resistant to TGF-b inhibition.. Journal of Clinical Oncology. 42(16_suppl). e14533–e14533. 2 indexed citations

2.

Akkari, Leila, Robert L. Bowman, Florian Klemm, et al.. (2020). Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Science Translational Medicine. 12(552). 221 indexed citations

3.

Rozeman, Elisa A., Jules Gadiot, Marnix H. Geukes Foppen, et al.. (2017). Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial). Annals of Oncology. 28. v446–v446. 3 indexed citations

4.

Rozeman, Elisa A., Jules Gadiot, Marnix H. Geukes Foppen, et al.. (2017). Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial). Annals of Oncology. 28. v447–v447. 1 indexed citations

5.

Gadiot, Jules, Ekaterina S. Jordanova, Ruben Lacroix, et al.. (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology. 5(12). e1238557–e1238557. 120 indexed citations

6.

Kroon, Paula, Jules Gadiot, Alessia Gasparini, et al.. (2016). Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology Immunotherapy. 65(6). 753–763. 26 indexed citations

7.

Guislain, Aurélie, Jules Gadiot, Andrew Kaiser, et al.. (2015). Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunology Immunotherapy. 64(10). 1241–1250. 94 indexed citations

8.

Gadiot, Jules, et al.. (2013). Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. OncoTargets and Therapy. 6. 1649–1649. 10 indexed citations

9.

Mougiakakos, Dimitrios, Riki Okita, Takashi Ando, et al.. (2012). High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis. Journal of Molecular Medicine. 90(8). 935–944. 22 indexed citations

10.

Hooijkaas, Anna I., Jules Gadiot, Martin van der Valk, Wolter J. Mooi, & Christian U. Blank. (2012). Targeting BRAF in an Inducible Murine Model of Melanoma. American Journal Of Pathology. 181(3). 785–794. 49 indexed citations

11.

Kaiser, Andrew, Jules Gadiot, Aurélie Guislain, & Christian U. Blank. (2012). Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. Cancer Immunology Immunotherapy. 62(3). 503–515. 9 indexed citations

12.

Westerman, Bart A., Marleen Blom, Ellen Tanger, et al.. (2012). GFAP-Cre-Mediated Transgenic Activation of Bmi1 Results in Pituitary Tumors. PLoS ONE. 7(5). e35943–e35943. 15 indexed citations

13.

Hooijkaas, Anna I., Jules Gadiot, Michelle Morrow, et al.. (2012). Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology. 1(5). 609–617. 60 indexed citations

14.

March, H. Nikki, Alistair G. Rust, Nicholas A. Wright, et al.. (2011). Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nature Genetics. 43(12). 1202–1209. 152 indexed citations

15.

Kaiser, Andrew, Jules Gadiot, Lisa Borkner, et al.. (2011). Reduced tumor‐antigen density leads to PD‐1/PD‐L1‐mediated impairment of partially exhausted CD8⁺ T cells. European Journal of Immunology. 42(3). 662–671. 13 indexed citations

16.

Hooijkaas, Anna I., Jules Gadiot, Hester van Boven, & Christian U. Blank. (2011). Expression of the embryological morphogen Nodal in stage III/IV melanoma. Melanoma Research. 21(6). 491–501. 8 indexed citations

17.

Kool, Jaap, Anthony G. Uren, Daoud Sie, et al.. (2010). Insertional Mutagenesis in Mice Deficient for p15Ink4b, p16Ink4a, p21Cip1 , and p27Kip1 Reveals Cancer Gene Interactions and Correlations with Tumor Phenotypes. Cancer Research. 70(2). 520–531. 25 indexed citations

18.

Gadiot, Jules, et al.. (2010). Overall survival and PD‐L1 expression in metastasized malignant melanoma. Cancer. 117(10). 2192–2201. 196 indexed citations

19.

Strizzi, Luigi, Lynne‐Marie Postovit, Naira V. Margaryan, et al.. (2009). Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Review of Dermatology. 4(1). 67–78. 56 indexed citations

20.

Gadiot, Jules, et al.. (2009). Homeostatic proliferation of naïve CD8⁺ T cells depends on CD62L/L‐selectin‐mediated homing to peripheral LN. European Journal of Immunology. 39(11). 2981–2990. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact